We developed a novel nanoplatform-based MMP9-responsive T2–T1 switching MRI contrast agent, which can be used not only for non-invasive visualization and quantitative analysis of MMP9 activity, but also as a carrier in photothermal sensitization chemotherapy. The nanoplatform acts as a T2 contrast agent in physiological conditions ,then transform into a T1 contrast agent by MMP9 stimulus. We have demonstrated that the changes R1 and R2/R1 values are MMP9 concentration dependent in tumors. The combination of PMPSD with laser irradiation was more effective than single chemo-/photothermal therapy, and up-regulation of MMP9 in the tumor could eanhance the nanoplatform’s therapeutic effect.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: